Shares of PerkinElmer, Inc. (NYSE:PKI – Get Rating) have been given a consensus recommendation of "Hold" by the eleven research firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $162.50.

A number of analysts have recently weighed in on PKI shares. Bank of America cut PerkinElmer from a "buy" rating to a "neutral" rating and set a $178.00 price target on the stock. in a research report on Tuesday, August 2nd. Barclays lowered their target price on PerkinElmer from $149.00 to $140.00 and set an "underweight" rating on the stock in a research report on Monday, September 12th. Stifel Nicolaus cut PerkinElmer from a "buy" rating to a "hold" rating and lowered their target price for the company from $190.00 to $170.00 in a research report on Thursday, August 18th. Robert W. Baird raised their target price on PerkinElmer from $198.00 to $202.00 and gave the company an "outperform" rating in a research report on Tuesday, August 2nd. Finally, UBS Group started coverage on PerkinElmer in a research report on Wednesday, July 20th. They issued a "buy" rating and a $160.00 target price on the stock.

PerkinElmer Trading Down 1.4 %

NYSE:PKI opened at $125.95 on Thursday. The company has a quick ratio of 1.42, a current ratio of 2.02 and a debt-to-equity ratio of 0.63. The business's 50 day moving average is $143.28 and its two-hundred day moving average is $150.73. The company has a market cap of $15.90 billion, a PE ratio of 23.59, a P/E/G ratio of 0.36 and a beta of 1.14. PerkinElmer has a 52 week low of $125.52 and a 52 week high of $203.16.

PerkinElmer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, November 11th. Stockholders of record on Friday, October 21st will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.22%. The ex-dividend date is Thursday, October 20th. PerkinElmer's dividend payout ratio (DPR) is presently 5.24%.

Insider Activity

In other news, insider James M. Mock sold 5,025 shares of PerkinElmer stock in a transaction on Friday, June 24th. The stock was sold at an average price of $145.49, for a total transaction of $731,087.25. Following the transaction, the insider now directly owns 27,577 shares in the company, valued at approximately $4,012,177.73. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, insider James M. Mock sold 5,025 shares of the firm's stock in a transaction on Friday, June 24th. The stock was sold at an average price of $145.49, for a total transaction of $731,087.25. Following the completion of the sale, the insider now directly owns 27,577 shares of the company's stock, valued at approximately $4,012,177.73. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Andrew Okun sold 3,173 shares of the firm's stock in a transaction on Monday, August 1st. The stock was sold at an average price of $165.42, for a total value of $524,877.66. Following the sale, the insider now directly owns 6,391 shares of the company's stock, valued at $1,057,199.22. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 13,898 shares of company stock worth $2,083,263. 0.52% of the stock is owned by company insiders.

Institutional Investors Weigh In On PerkinElmer

Several large investors have recently modified their holdings of PKI. HighTower Advisors LLC boosted its stake in shares of PerkinElmer by 16.8% during the 4th quarter. HighTower Advisors LLC now owns 6,258 shares of the medical research company's stock worth $1,260,000 after acquiring an additional 900 shares in the last quarter. American International Group Inc. boosted its position in shares of PerkinElmer by 12.8% in the fourth quarter. American International Group Inc. now owns 38,540 shares of the medical research company's stock worth $7,749,000 after buying an additional 4,378 shares during the period. Invesco Ltd. boosted its position in shares of PerkinElmer by 20.3% in the fourth quarter. Invesco Ltd. now owns 1,158,185 shares of the medical research company's stock worth $232,866,000 after buying an additional 195,758 shares during the period. Public Sector Pension Investment Board boosted its position in shares of PerkinElmer by 11.3% in the fourth quarter. Public Sector Pension Investment Board now owns 21,061 shares of the medical research company's stock worth $4,235,000 after buying an additional 2,130 shares during the period. Finally, Siemens Fonds Invest GmbH boosted its position in shares of PerkinElmer by 3.5% in the fourth quarter. Siemens Fonds Invest GmbH now owns 4,150 shares of the medical research company's stock worth $828,000 after buying an additional 140 shares during the period. 77.06% of the stock is owned by institutional investors.

About PerkinElmer

(Get Rating)

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.

See Also

• Get a free copy of the StockNews.com research report on PerkinElmer (PKI)
• The Worst May be Over for Target, But is the Stock Safe to Buy?
• Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
• Two Fun Stocks The Insiders Are Buying
• Novavax Remains a Risk-On Stock in a Risk-Off Market
• 3 Defensive Stocks With 60-Year Dividend Hike Streaks

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.